Adjuvant therapy after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains a topic of debate due to limited evidence supporting its efficacy. The primary aim of adjuvant therapy is to improve survival and reduce recurrence risk. While certain agents, like Licartin and sorafenib, have shown potential in small studies, larger randomized trials are needed to confirm their effectiveness and safety. Evidence from limited studies indicates a possible benefit of using systemic therapy, particularly in high-risk patients, but outcomes have been mixed and generally inconclusive. With the current lack of definitive data, adjuvant therapy post transplant is not routinely recommended outside of clinical trials. Further research is essential to establish whether adjuvant systemic therapy can provide substantial benefits for posttransplant HCC patients.